==== Front Molecules Molecules molecules Molecules 1420-3049 MDPI 33276545 10.3390/molecules25235685 molecules-25-05685 Review Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis https://orcid.org/0000-0003-4532-9128Alghamdi Saad 1 Rehman Shaheed Ur 2* Shesha Nashwa Talaat 3 Faidah Hani 4 https://orcid.org/0000-0002-8375-8532Khurram Muhammad 2* https://orcid.org/0000-0002-0880-0358Rehman Sabi Ur 2 1 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Mecca 24321, Saudi Arabia; ssalghamdi@uqu.edu.sa 2 Department of Pharmacy, Abasyn University Peshawar, Khyber Pakhtunkhwa 25000, Pakistan; sabi.rehman@abasyn.edu.pk 3 Regional Laboratory, Directorate of Health Affairs Makkah, Mecca 24321, Saudi Arabia; nshesha@moh.gov.sa 4 Microbiology Department, Faculty of Medicine, Umm Al-Qura University, Mecca 24321, Saudi Arabia; hsfaidah@uqu.edu.sa * Correspondence: shaheed.rehman@abasyn.edu.pk (S.U.R.); muhammad.khurram@abasyn.edu.pk (M.K.); Tel.: +923459832402 (S.U.R.) 02 12 2020 12 2020 25 23 568515 10 2020 01 12 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen, meager dosing, and the capability of the latent and/or active state tubercular bacilli to abide and do survive against contemporary first-line and second line antitubercular drugs escalate the prevalence of drug-resistant tuberculosis. As a better understanding of tuberculosis, microanatomy has discovered an extended range of new promising antitubercular targets and diagnostic biomarkers. However, there are still no new approved antitubercular drugs of routine therapy for several decades, except for bedaquiline, delamanid, and pretomanid approved tentatively. Despite this, innovative methods are also urgently needed to find potential new antitubercular drug candidates, which potentially decimate both latent state and active state mycobacterium tuberculosis. To explore and identify the most potential antitubercular drug candidate among various reported compounds, we focused to highlight the promising lead derivatives of isoniazid, coumarin, griselimycin, and the antimicrobial peptides. The aim of the present review is to fascinate significant lead compounds in the development of potential clinical drug candidates that might be more precise and effective against drug-resistant tuberculosis, the world research looking for a long time. drug-resistant tuberculosisisoniazid derivativescoumarin derivativesantimicrobial peptides ==== Body 1. Introduction Mycobacterium is a genus of Actinobacteria, acid-fast, aerobic, and nonmotile bacteria. This genus contains opportunistic pathogens known to cause serious diseases, especially in the clinical setting. Mycobacterium tuberculosis, the etiological agent of tuberculosis is one of the leading causes of morbidity and mortality in humans [1]. In 80–90% of the cases, these aerobic bacilli enter the lungs, while other extrapulmonary organs, primarily lymph nodes, bones, joints, and the genitourinary system are affected as well [2]. The primary route of transmission of the bacilli into the human lungs is via aerosol droplets [3,4,5]. According to WHO report, globally, about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with diabetes and HIV are present [6]. Drug-resistant tuberculosis is a growing threat to public health. Around half a million new rifampicin-resistant tuberculosis cases (78%—multidrug-resistant tuberculosis) emerged in 2018. Globally, 3.4% of new cases of tuberculosis had multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) and 18% of previously treated patients [6,7]. In 2018, an estimated 1.2 million deaths from tuberculosis were reported in HIV negative persons, while further 251,000 deaths among HIV-positive cases [6] were observed. Tuberculosis coinfection with HIV also raises the risk of relapse per year by up to 10%. Therefore, in patients with HIV coinfection, tuberculosis is the primary cause of death [7]. Antibiotic therapy prolongation contributes to the development of antibiotic resistance. Drug-resistant tuberculosis is an emerging public health threat in many countries of the world. Moreover, the extended duration of antibiotic treatment raises the risk of noncompliance, adverse effects, and drug toxicity. Therefore, it is urgent to find a way to strengthen the current antibiotic therapy regimen against drug-resistant tuberculosis [8]. The process of novel drug development to fight out the resistant strains of tubercular infections has been considered for a long time, and some of the significant candidates are in various stages of clinical trials [9]. Unfortunately, the drug development and approval processes are too lengthy, and these agents are often generally not as effective as expected. In tuberculosis chemotherapy, the other major problem is the relative refractory of mycobacteria to killing by antibiotics or immune systems and the development of resistant strains [10]. Recent advancements in molecular biology and mycobacterial disease immunopathogenesis have contributed to substantial studies in such research areas. Numerous vaccines are manufacturing for prevention or therapeutic purposes [11,12]. We should, however, wait in the coming years for accessible and reliable vaccines. The problematic scenario is the relationship among the host cells and tubercle bacilli afterwards the primary infection occurs, which results in latent tuberculosis infection in most cases. As described earlier, the human body can contain the disease in >80% of the cases, and the bacilli remain dormant throughout infected peoples’ entire lives. This phenomenon has been the topic of extensive research [13,14,15]. It is worth mentioning that the WHO, international organizations, educational agencies, foundations, and sponsors are working together to resolve dissimilar facets of the topic and to accomplish the anticipated goals in the approaching periods. The development of drug-resistant strains of mycobacterium tuberculosis illustrates the importance and demand for an early identification of drug-resistant strains, exploring new targets for drug sensitivity, customized treatment plans, and more effective medical interventions. Literature shows several studies, incorporating bioinformatics and proteomics approaches that clearly indicate the potential drug targets and an early diagnostic against drug-resistant strains [16,17,18,19,20]. To tackle the alarming condition of antimicrobial resistance, pathogen-centric approach covering novel chemotherapeutics and novel diagnostic pathways, along with host targeted therapeutics (i.e., host immune system modulators to treat pathogenesis), must be appraised [21,22,23,24,25]. The efficacy of novel chemotherapeutic agents (i.e., delamanid and bedaquiline), which currently have approval from USFDA, are now compromised by the successional pathogen tolerance strategies [26,27,28,29,30]. Novel antitubercular repurposed drugs as combinational treatment solutions (new anti-TB drug schedules) and host-directed therapeutics may be measured to tackle the antibiotic resistance, which is a major problem to tuberculosis management. To combat the antibiotic resistance, the key problem in tuberculosis management, we have to identify the most promising lead compounds among new emerging antitubercular agents and conclude these compounds to clinical trials as potential antitubercular drug candidates, along with considering the host-targeted therapeutics. The use of accelerated molecular microbiological techniques will be the near future of tuberculosis management [12]. Drug tests for susceptibility tests may be either phenotypic or genotypic. Phenotypic tests for drug susceptibility are commonly used with prime focus on measuring bacterial growth with first-line, e.g., isoniazid, ethambutol (EMB), rifampicin, and streptomycin [SM]), or second-line antitubercular medicines at defined concentrations. This method has certain advantages that it is fast and economical, but has disadvantage of substantial interruptions and is not reliable for use of ethambutol and other medicine. Genotypical strategies take benefit of particular transmutations relevant to the response against specific medications [13]. Molecular approaches should be conducted using sputum or any other samples and can yield results in a very short period of time (including drug susceptibility). The most used strategies are discussed below:GenXpert MTB/RIF is an assay for nucleic acid amplification in sputum sample that analyses DNA and RIF resistance for the presence of mycobacterium tuberculosis. It is a very simple and reproducible procedure with 90% sensitivity and 99% accuracy. The GenXpert is an automated assay and requires no laboratory arrangements. Rifampicin resistance detection is also used for the prediction of MDR-tuberculosis with isoniazid resistance (in most of the cases) [14]. As an initial diagnostic examination, the WHO recently proposed GenXpert for patients with HIV supposed to have tuberculosis or for those who are at risk for rifampicin resistance and/or MDR tuberculosis. GenXpert (MTB/RIF) Ultra is theoretically facilitating, more precise, and sensitive bedside testing that can enhance tuberculosis detection in smear-negative patients, and similar assays are currently under development. Line probe assay (LPA), approved by WHO, is family of DNA strip-based tests for swift recognition of first- and second-line antitubercular agents drug resistance [31]. It can also be used for testing culture isolates along with direct testing of acid-fast bacilli as well as smear-positive and -negative sputum specimens. LPA can determine the frequently identified mutations in resistant strains [14,15]. 2. Compounds with Promising Antimycobacterial Potentials Ethambutol, isoniazid, pyrazinamide, rifampicin, amikacin, cycloserine, rifabutin, amoxicillin-clavulanic acid, streptomycin, clofazimine, bedaquiline, aminosalicylic acid, delamanid, ethionamide, moxifloxacin, levofloxacin, linezolid, meropenem, and rifapentine are currently included in the list of essential WHO antituberculosis medications (WHO 2019). The three newly approved bedaquiline, delamanid, and pretomanid showed adverse events and complications when concomitantly used with other antitubercular drugs, and so, they could not be prescribed under routine treatment. Novel antitubercular medicines are less effective, while still a very limited number of the investigational drug compounds are subjected to human clinical trials. 2.1. Classification of Antitubercular Drugs In the current classification, antitubercular drugs are classified into four groups, i.e., A, B, C, and D (Table 1) [32]. In this classification, it is precisely configured to incorporate the treatment of rifampicin-resistant or MDR-tuberculosis [33]. Group-A contains fluoroquinolones (high doses of levofloxacin, moxifloxacin, and gatifloxacin). Due to their bactericidal and sterilizing efficacy and strong safety profile, these are called vital products. Group-B contains injectable products like (streptomycin, kanamycin, amikacin, and capreomycin) that are incredibly bactericidal but have a lower safety rating than drugs in Group A. Ethionamide, cycloserine/terizidone, clofazimine, prothionamide, and linezolid are in Group-C. Given increasing proof of their effectiveness and tolerability, these medications are recommended as vital second-line medicines for multidrug-resistant tuberculosis. Group-D is classified into three subgroups: D1: large-dose isoniazid, ethambutol, and pyrazinamide; D2: delamanid and bedaquiline; and D3: para-aminosalicylic acid, meropenem, cilastatin-imipenem, clarithromycin, and clavulanate-amoxicillin. Some of the emerging novel drugs have the ability to be used as adjunct in the abovementioned antitubercular regime. The inclusion of such drugs in tuberculosis therapeutics will steer synergistic effects and can lead to improved outcomes by increasing effectiveness against resistant mycobacterium tuberculosis strains (like isoniazid hydrazides and nitazoxanide) or by negating mechanisms of the resistance (like dihydropyridomycin). Furthermore, the development of isoniazid hydrazides and primaquine derivatives enhance the probability of improving patient compliance by decreasing adverse drug reactions and complications. It is promising to see that many potential new candidate compounds being proposed are in pipeline to be significantly used as either monotherapy or combination therapy options to eradicate tuberculosis. However, a variety of prospective drug candidates having direct and/or indirect antitubercular action (just like sildenafil, mefloquine, cilostazol, tizoxanide, metronidazole, entacapone, tolcapone, and ibuprofen) are reported to have high efficacy during in vitro studies as mycobacterial monotherapy or in adjunctive action [31,34]. These compounds need to be tested in vivo and, later on, in human clinical trials. In enlightenment of the above statement, it is crucial to participate in the recent antitubercular drug discovery campaign that focuses on designing drug regimens capable of shortening treatment duration as well as fight out complicated drug resistance tuberculosis. Thus, it is important to highlight the potential antitubercular drug candidates among others, so, to pursue further research and in vivo studies based on drug safety and efficacy against drug-resistant mycobacterium strains. 2.2. Promising Novel Chemotherapeutics 2.2.1. Isoniazid Lead Derivatives Isoniazid (isonicotinic hydrazide, pyridine-4-carbohydrazide, and INH) is one of the most significant and efficient first-line antitubercular drugs in tuberculosis therapeutics around the world. Since 1952, isoniazid has been extensively used as a prodrug, which is activated by catalase-peroxidase (KatG), the mycobacterial multifunctional enzyme. The inhibition of mycolic acids synthesis, a distinct building block in the mycobacterium cell wall and accountable for its prominent lipophilic nature, is the main target of isoniazid. The activated isoniazid molecule is responsible for suppressing biosynthesis of mycolic acid by enoyl-ACP reductase inhibition, an enzyme elaborated in the biosynthesis of fatty acid in the existence of NAD+ or NADH [35]. So, the enoyl-ACP reductase is considered one of the finest-validated targets in the therapeutics of tuberculosis. Isoniazid resistance is mostly mediated by the mutations of the katG gene, which leads to the drug activation incapability, one of the prominent factors responsible for mycobacterium tuberculosis resistance in the clinical settings [36]. The mutation rate liable for isoniazid resistance is 100 times greater than rifampicin mutation [37]. Castelo-Branco et al. [38] reported certain isoniazid hydrazide compounds labeled 14, 15, and 16 with striking antimycobacterial potency and decreased hepatotoxicity (lower toxicity to HepG2 cells) as compared to the parent isoniazid compounds. Results showed that mycobacterium strains with both isoniazid KatG (SR 0215, SR 2571, and T113) and rifampicin rpoB (T09) mutations were particularly vulnerable to these isoniazid hydrazides. The MIC for 2-Cyano-N-(4-methylphenyl) acetamide, 2-Chloro-N-(2,6-diethylphenyl) acetamide, and 2-Phenylacetamide were 0.45, 0.43, and 0.47 μM, respectively. There mycobacterial activity is reliant on the isonicotyl attachment and may be contrary to isoniazid molecule. In contrast, isoniazid was mutagenic at 50 μM, while its analogs reflected mutagenicity at concentrations >500 μM, under the same assay conditions. Table 2, represents selected chemotherapeutic derivatives and antimicrobial peptides, their molecular targets, mechanism of action, and investigated MIC range for the promising lead compounds. Loots [39] reported that isoniazid was less vulnerable to isoniazid-resistant strains by upregulating the fatty acids and alkanes use and synthesizing bioactive moieties specifically pertain to oxidative stress relief, including those linked to a novel degradation mechanism of ascorbic acid. Isoniazid, due to its emerging sensitive resistant issues, is going to left out from therapeutic regimens, which endorse the researcher to develop more active novel isoniazid lead derivatives, specifically tailored to target multidrug-resistant tuberculosis. Novel research approaches targeting KatG mutation metabolic schemes and biomarkers have pledged opportunities, which will oblige the discovery of novel isoniazid lead derivatives. 2.2.2. Coumarin Lead Derivatives The coumarin ring system (chromen-2-one or benzopyran-2-one), existing in natural products that exhibit promising pharmacological properties, has enthralled researchers for decades to probe natural coumarins and their synthetic analogs as potential drug candidates for a wide range of ailments. Coumarins act as intermediate in the synthesis of chromenes, coumarones, furocoumarins, and 2-acylresorcinols [57]. Coumarin and most of its derivatives possess a wide range of therapeutic effects such as antimicrobial [58,59,60,61,62,63], antioxidant [64,65,66], antidepressant [67,68,69], anti-inflammatory [70,71,72,73,74], antitumor [75,76,77,78,79], antinociceptive [80,81,82], antiasthmatic [83,84,85], anti-Alzheimer [85,86,87,88], antipyretic [89,90], and antihyperlipidemic [91,92,93,94] activities. A substantial effort has been made in past few decades to explore coumarin-based entities as antitubercular drug, which is agile against clinically approved therapeutic targets reflecting terrific therapeutic outcomes. Over the years, studies on the antimicrobial function of coumarin-based compounds have increased. Coumarin functional nucleus substituted with varied moieties at all positions has resulted in potent antitubercular activity, except for position 1 and 2 [95]. Coumarins have several biological properties that include the inhibition of mycobacterium tuberculosis [96,97,98] and are dependent on structural stability and the scaffolding potential of the parent coumarin compound [45]. Reddy et al. [41] has recently investigated the synthesis of two unique coumarin derivatives, dimethyl substituted compound (1e) and a coumarin-oxime ether derivative (1h), both of which showed excellent antituberculosis activity having MIC of 0.32 and 0.12 μM, respectively. This range is quite comparable to first-line antitubercular drug isoniazid. According to Mangasuli et al. [42], a coumarin-theophylline hybrid (3a) demonstrated strong binding associations with MTB 4DQU enzymes and potential antimicrobial properties over a broad-spectrum inhibiting Staphylococcus aureus, Escherichia coli, Candida albicans, and Salmonella typhi. Possible antituberculosis mechanism of action manifested by coumarin derivatives implies cytochrome synthesis disruption, suppression of cell proliferation, macrophage activation, and kinase inhibitor [43]. The insertion of other substituents of interest like heterocyclic moieties and oximes, in the coumarin basic nucleus, could anticipate direction for synthesizing potential novel antitubercular lead compounds. Natural coumarin 6-((3,3-dimethyloxiran-2-yl)-5,7-dihydroxy-8-(2-methylbutanoyl)-4-phenyl-2H-chromen-2-one (1g) exhibited the best anti-M. tuberculosis activity with IC50 value of 47.4 μM [41]. Among the synthetic coumarin derivatives, compounds 4-Hydroxy-7-methoxy-2H-chromen-2-one (LSPN270), 7-Ethoxy-4-hydroxy-2H-chromen-2-one (LSPN271), 4-Ethyl-2-hydroxy-4,4a-dihydropyrano[3,2-c]-chromen-5(10bH)-one (LSPN476), and 8-Ethoxy-4-ethyl-2-hydroxy-3,4-dihydropyrano[3,2-c]-chromen-5(2H)-one (LSPN484), which showed MIC from 63.4 μM (≤62.5 μg/mL) against the reference strain and selectivity index between 1.07 and 4.27, demonstrated significant activity against MDR M. tuberculosis clinical isolates (Figure 1) [44]. According to Pires et al. [44], compounds 1g, LSPN270, LSPN271, LSPN476, and LSPN484 may be considered potential candidates for further studies in developing new antitubercular drugs. 2.2.3. Griselimycin Lead Derivatives Griselimycin and its variant methylgriselimycin are natural cyclic compounds synthesized from Streptomyces strain DSM 40835 in the 1960s, which exhibit promising antibacterial and antimycobacterial activity against the resistant strains of M. tuberculosis [99]. Early studies indicated unfavorable pharmacokinetics of griselimycin, given an edge to rifampicin, which was approved at parallel time frame, while the development of griselimycin as antimycobacterial drug was break off. It was determined that the cocrystal structures of griselimycin derivatives attach to DnaN, representing that DnaN peptide-binding pockets have been employed by the cyclic part of the griselimycin antibiotics. The appraisal of the self-resistance to griselimycin in Streptomyces and griselimycin resistance in mycobacterium exhibited amplification of DnaN gene. The DNA polymerase sliding clamp that tie-up the DNA polymerase to DNA and thus confers replicative enzyme responsible for the DNA repair and replication acceleration in prokaryotes [47]. Rolf Müller and his team determined to upgrade griselimycin, considering its promising bioactivity [48]. Primarily, they enhanced the metabolic stability of griselimycin by the addition of alkylation to the proline residue on position 8. Cyclohexyl griselimycin, a synthetic analog of griselimycin, was metabolically stable and showed enhanced lipophilicity and penetration to the thick cell wall of mycobacterium, resulting in superb antimycobacterial activity, with a MIC value of 0.05 μM against the compound susceptible to the mycobacterium tuberculosis H37Rv strain and 0.17 μM for macrophage-like cell encapsulated same strain (RAW264.7) [47,49]. By attacking the DnaN (sliding clamp that anchors the DNA to DNA polymerase), cyclohexyl griselimycins works against mycobacterium tuberculosis and ultimately prevents the proliferation and regeneration of mycobacterial DNA [47,48]. Besides this, significant antimycobacterial activity in acute and chronic tuberculosis mouse models has revealed its synergistic properties with rifampicin and pyrazinamide, with likelihood of indication for shortening the length of the tuberculosis course [100]. 2.3. Lead Antimicrobial Peptides Antimicrobial peptides (AMPs) also known as host defense peptides are distinguished part of the innate immune response acquired among all type of life. They are the positively charged peptides, encompasses about 12-to-50 amino acids residue [101,102,103]. The existence of the positively charged amino acids moieties, like arginine and lysine, provides a net positive charge to AMPs. The AMPs have hydrophilic and hydrophobic regions, responsible for their amphipathic character, enabling their junction with biological cell membranes while retaining aqueous solubility [32,33]. Following their secondary molecular structure, AMPs are categorized into four categories: α-helix, β-sheet, β-hairpin, and linear non-α-helical loop [104,105]. AMPs principally applied their actions by direct interaction with microbial cell membrane. Therefore, antibacterial specificity and selectivity of AMPs over the host are quite remarkable. The physiochemical and structural characteristics, including general charge, charge angle, length, conformation, amphipathicity, hydrophobicity, and solubility, exert considerable effect on the behavior of AMPs [106,107]. Antimicrobial peptides execute an essential role in the generation of innate immune response, having modulating capability of the host cellular immunity. AMP expedite pathogen clearance effective for bacteria, viruses, fungi, and parasites, claiming their broad-spectrum antimicrobial coverage. Peptides have been reported to induce the breakdown or alteration of bacterial cell walls and the cytoplasmic elements condensation. AMPs hit the cell wall by various modes of action, like pore formation, thinning, altered curvature, modified electrostatics, and localized perturbations [108]. It has been reported that the cell membrane and cell wall are the primary cathelicidin-based peptide targets, through inserting osmotic action, cell wall synthesis destruction, and likely DNA binding [109]. AMPs are the emerging investigational agents that play major role in novel drug development process, and some of them are in Phases-II and -III clinical trials, reflecting their significance and trend in the near future. Interestingly, none of the AMP is in clinical trials for the treatment of tuberculosis. Although many research studies reported significant antimycobacterial activity for AMPs, and even considering the preclinical trials of MU1140 (Oragenics, Inc., Tampa, FL, USA), the essential role of AMPs in tuberculosis therapeutics is clearly indicated. Several in vitro and in vivo studies revealed significant efficacy of AMPs against drug-resistant strains of mycobacterium. A proline-arginine-rich AMP, PR-39, has proved to be effective against clinical isolates of multidrug-resistant strain of mycobacterium tuberculosis [110,111]. Fattorini et al. [112] confirmed the inhibitory effect of β-defensin-1 and protegrin-1 against drug-resistant mycobacterium tuberculosis growth. One other research study investigated the MICs of synthetic peptides from cecropin A and melittin B hybrid against multidrug-resistant strain of tuberculosis [54]. Most of these tested peptides significantly inhibit the growth of multidrug-resistant tuberculosis strain, having MICs comparable to the ones exhibited from susceptible H37Rv strain. AMPs consisting of D-LAK group, having D-amino acids, was also revealed to inhibit multidrug resistance and extended drug resistance strains of tuberculosis, both in vitro and ex vivo [113]. The LL37 (cathelicidin) manifested to have promising efficacy against H37Rv and drug-resistant strains of mycobacterium in the infected mice [53]. Moreover, 1-month treatment regimen of LL37 (32 μg, three times/week/mouse) indicated for the reduction in up to 53% of mycobacterial number. It has been denoted that the expression of LL37 is impelled in macrophages due to mycobacterial infection (Figure 2) [114,115]. A 26 amphipathic peptide residue, D-V13 K, comprising all D-amino acids, has positively charged lysine and valine at position no. 16, as “specificity determinant.” It was identified the most effective analog against mycobacterium tuberculosis having MIC value of 15.6 and 11.2 μM against multidrug-resistant and H37Rv strains, respectively. Peptide D1, having positively charged residue of lysine at the center, demonstrated D5 comparable mycobacterial activity against the multidrug-resistant strains of tuberculosis (i.e., 57 μg/mL) and had therapeutic index at 7.4-fold higher than D5 [54]. In comparison, D-LAK120-HP13 and D-LAK120-A demonstrated the optimum potency and did not detect mycobacterium in wells at concentration of 50 μM and above. AMPs’ nonpolar portion has been incorporated into the membrane bilayer and peptide aggregation, resulting in increased permeability, diminish barrier function, cytoplasmic components disintegration, and ultimately cell death [54]. Bacteriocins (Bcns1–Bcn5) group of peptides from different Gram +ev bacteria has been shown to have improved antimycobacterial action against mycobacterium tuberculosis [55]. Sosunov et al. [55], reported that Bcn4 exhibit excellent bacteriostatic capacity at concentration of 0.1 μg/mL, which is almost 10-fold lower than rifampicin MIC50 value. The mechanism of action taken by Bcn1–Bcn5 against mycobacterium tuberculosis is found on the formation of pores in cell membranes, progressing cell death [116,117,118]. The activities of nisin-A and recent biosynthesized hinge derivatives, i.e., nisin-T, nisin-V, and nisin-S, are evaluated for antimycobacterial activity. Both variants indicated an extra antimicrobial activity compared to nisin-A. The nisin-S was reported as the potent one, effective against mycobacterium tuberculosis and mycobacterium avium, eradicating their growth by a rate of 29% relative to nisin-A [56]. Cathelicidins is a large class of mammalian AMPs that are considered an essential part of the innate immunity, producing rapid and nonspecific response to pathogens. By regulating cytokine proinflammatory responses, calcium influx, and apoptosis, cathelicidins are substantially recommended as an essential, multifunctional immune regulators with ultimate antimycobacterial activity by the virtue of host adaptive immune responses. The preventive function of cathelicidins in tuberculosis infection depends on the cAMP bursts in macrophages that are activated by mycobacterium, provides tuberculosis pathogenesis clue, and encourages further research into cathelicidin-mediated immune control [52]. NOX2 induces phagocytic activity against intracellular bacilli via the formation of reactive oxygen species (ROS). Yuk et al. [119] reported that NOX2 is necessary for D3-mediated antimycobacterial action via cathelicidin expression. To the best our knowledge, studies scrutinizing the antimycobacterial use of AMPs against drug-resistant mycobacterium tuberculosis have not still got into preclinical trials. However, considering the emerging trend of AMPs and its essential role in the treatment of drug-resistant tuberculosis, it is rational to anticipate such studies in the very near future. 3. Conclusions Incomplete therapeutic regimen, meager dosing, and the capability of the latent and/or active state tubercular bacilli to abide and to survive against contemporary first-line and second-line antitubercular drugs escalate the prevalence of drug-resistant tuberculosis. It is still a challenge for the pharmaceutical scientists to develop the most promising drug substitute among available favorite drug candidates that potentially cover the resistant strain of mycobacterium tuberculosis. In this article, we are fascinated to find the potential drug candidates and their precise tailored derivatives, having promising antimycobacterial properties, but are still on a slow track in clinical research prospective. Our findings suggested the emerging role and scope of antimicrobial peptides and the lead derivatives of coumarin, isoniazid, and griselimycin having strong antimycobacterial activity in laboratories, which need to accelerate their further in vivo studies. Clinical research on these promising compounds possibly leads to potential antitubercular drug candidate that might be more precise and effective against drug-resistant tuberculosis. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Funding This research received no external funding. Conflicts of Interest The authors declare no conflict of interest. Figure 1 Chemical structure of lead isoniazid, coumarin and griselimycin derivatives with minimum inhibitory concentrations (MICs) value. Figure 2 Mechanism of action for isoniazid, coumarin, and griselimycin derivatives and antimicrobial peptides (AMPs). molecules-25-05685-t001_Table 1Table 1 WHO classification of antitubercular drugs. Drug Class Included Drugs (A) Fluoroquinolones Levofloxacin, gatifloxacin, moxifloxacin (B) Second-line injectables Streptomycin, kanamycin, amikacin, capreomycin (C) Other core second-line drugs Ethionamide, cycloserine/terizidone, prothionamide, linezolid, clofazimine (D) Noncore, multidrug-resistant tubercular drugs i. High dose—isoniazid, pyrazinamide, ethambutol ii. Delamanid and bedaquiline iii. Para-aminosalicylic acid, meropenem, cilastatin-imipenem, clarithromycin, clavulanate-amoxicillin molecules-25-05685-t002_Table 2Table 2 Selected chemotherapeutic derivatives and antimicrobial peptides, their molecular targets, mechanism of action, and investigated minimum inhibitory concentration (MIC) range. Drug Class Lead Compounds Molecular Targets/Mechanism of Action MIC Range References Isoniazid derivatives 2-Cyano-N-(4-methylphenyl) acetamide, 2-Chloro-N-(2,6-diethylphenyl) acetamide, 2-Phenylacetamide Inhibition of mycolic acid synthesis and cell growth inhibitor 0.43–0.47 μM [38,39,40] Coumarin derivatives 6-((3,3-dimethyloxiran-2-yl)-5,7-dihydroxy-8-(2-methylbutanoyl)-4-phenyl-2H-chromen-2-one (1g), Dimethyl substituted compound (1e), coumarin-oxime ether (1h), a coumarin-theophylline hybrid (3a), LSPN270, LSPN271, LSPN476, and LSPN484 Cell proliferation inhibitors, cytochrome synthesis disruption, and macrophages activation 0.12–148 μM [41,42,43,44,45] Griselimycin derivatives Cyclohexyl griselimycin Inhibits DNA repair and replication 0.05–0.17 μM [46,47,48,49] Antimicrobial peptides Bacteriocins (Bcn1–Bcn5), protegrin-1, nisin S, D-V13 K, cathelicidin LL37, D-LAK120-A, and D-LAK120-HP13 Multifunctional host immune regulators, pro-inflammatory cytokine responses regulator, calcium influx, and apoptosis 0.01–30 μM [50,51,52,53,54,55,56] ==== Refs References 1. World Health Organization (WHO) WHO Guidelines on Tuberculosis Infection Prevention and Control: 2019 Update World Health Organization Geneva, Switzerland 2019 2. Tiemersma E.W. van der Werf M.J. Borgdorff M.W. Williams B.G. Nagelkerke N.J. Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review PLoS ONE 2011 6 e17601 10.1371/journal.pone.0017601 21483732 3. Mehta A. Srivastva G. Kachhwaha S. Sharma M. Kothari S. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates J. Ethnopharmacol. 2013 149 195 200 10.1016/j.jep.2013.06.022 23816500 4. Tascon R. Soares C. Ragno S. Stavropoulos E. Hirst E. Colston M. Mycobacterium tuberculosis-activated dendritic cells induce protective immunityin mice Immunology 2000 99 473 480 10.1046/j.1365-2567.2000.00963.x 10712679 5. Tian T. Woodworth J. Sköld M. Behar S.M. In vivo depletion of CD11c+ cells delays the CD4+ T cell response to Mycobacterium tuberculosis and exacerbates the outcome of infection J. Immunol. 2005 175 3268 3272 10.4049/jimmunol.175.5.3268 16116218 6. World Health Organization Global Tuberculosis Report 2019 World Health Organization Geneva, Switzerland 2019 7. Harding E. WHO global progress report on tuberculosis elimination Lancet Respir. Med. 2020 8 19 10.1016/S2213-2600(19)30418-7 31706931 8. Dobbs T. Webb R. Chemotherapy of Tuberculosis Microbiol. Spectr. 2017 5 10.1128/microbiolspec.TNMI7-0040-2017 9. Shetye G.S. Franzblau S.G. Cho S. New tuberculosis drug targets, their inhibitors, and potential therapeutic impact Transl. Res. 2020 220 68 97 10.1016/j.trsl.2020.03.007 32275897 10. Young C. Walzl G. Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis Mucosal Immunol. 2020 13 190 204 10.1038/s41385-019-0226-5 31772320 11. Mangtani P. Abubakar I. Ariti C. Beynon R. Pimpin L. Fine P.E. Rodrigues L.C. Smith P.G. Lipman M. Whiting P.F. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials Clin. Infect. Dis. 2014 58 470 480 10.1093/cid/cit790 24336911 12. Kaufmann S.H. Evans T.G. Hanekom W.A. Tuberculosis vaccines: Time for a global strategy Sci. Transl. Med. 2015 7 fs8 fs276 10.1126/scitranslmed.aaa4730 13. Wayne L.G. Sohaskey C.D. Nonreplicating persistence of Mycobacterium tuberculosis Annu. Rev. Microbiol. 2001 55 139 163 10.1146/annurev.micro.55.1.139 11544352 14. Rustad T.R. Harrell M.I. Liao R. Sherman D.R. The enduring hypoxic response of Mycobacterium tuberculosis PLoS ONE 2008 3 e1502 10.1371/journal.pone.0001502 18231589 15. Cardona P. Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli Eur. Respir. J. 2004 24 1044 1051 10.1183/09031936.04.00072604 15572551 16. Lata M. Sharma D. Deo N. Tiwari P.K. Bisht D. Venkatesan K. Proteomic analysis of ofloxacin-mono resistant Mycobacterium tuberculosis isolates J. Proteom. 2015 127 114 121 10.1016/j.jprot.2015.07.031 17. Sharma D. Bisht D. Secretory proteome analysis of streptomycin-resistant Mycobacterium tuberculosis clinical isolates Slas Discov. Adv. Life Sci. R&D 2017 22 1229 1238 18. Sharma D. Bisht D.M. tuberculosis hypothetical proteins and proteins of unknown function: Hope for exploring novel resistance mechanisms as well as future target of drug resistance Front. Microbiol. 2017 8 465 10.3389/fmicb.2017.00465 28377758 19. Sharma D. Bisht D. Khan A.U. Potential alternative strategy against drug resistant tuberculosis: A proteomics prospect Proteomes 2018 6 26 10.3390/proteomes6020026 20. Sharma D. Lata M. Singh R. Deo N. Venkatesan K. Bisht D. Cytosolic proteome profiling of aminoglycosides resistant Mycobacterium tuberculosis clinical isolates using MALDI-TOF/MS Front. Microbiol. 2016 7 1816 10.3389/fmicb.2016.01816 27895634 21. Lee M. Lee J. Carroll M.W. Choi H. Min S. Song T. Via L.E. Goldfeder L.C. Kang E. Jin B. Linezolid for treatment of chronic extensively drug-resistant tuberculosis N. Engl. J. Med. 2012 367 1508 1518 10.1056/NEJMoa1201964 23075177 22. Sotgiu G. Centis R. D’Ambrosio L. Spanevello A. Migliori G.B. Linezolid to treat extensively drug-resistant TB: Retrospective data are confirmed by experimental evidence Eur. Respir. J. 2013 42 288 290 10.1183/09031936.00191712 23813314 23. Dua K. Rapalli V.K. Shukla S.D. Singhvi G. Shastri M.D. Chellappan D.K. Satija S. Mehta M. Gulati M. Pinto T.D.J.A. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches Biomed. Pharmacother. 2018 107 1218 1229 30257336 24. Alffenaar J. Van Der Laan T. Simons S. Van Der Werf T. Van De Kasteele P. De Neeling H. Van Soolingen D. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480 Antimicrob. Agents Chemother. 2011 55 1287 1289 10.1128/AAC.01297-10 21199931 25. Balasubramanian V. Solapure S. Iyer H. Ghosh A. Sharma S. Kaur P. Deepthi R. Subbulakshmi V. Ramya V. Ramachandran V. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis Antimicrob. Agents Chemother. 2014 58 495 502 10.1128/AAC.01903-13 24189255 26. Andries K. Villellas C. Coeck N. Thys K. Gevers T. Vranckx L. Lounis N. de Jong B.C. Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline PLoS ONE 2014 9 e102135 10.1371/journal.pone.0102135 25010492 27. Zimenkov D.V. Nosova E.Y. Kulagina E.V. Antonova O.V. Arslanbaeva L.R. Isakova A.I. Krylova L.Y. Peretokina I.V. Makarova M.V. Safonova S.G. Examination of bedaquiline-and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region J. Antimicrob. Chemother. 2017 72 1901 1906 10.1093/jac/dkx094 28387862 28. Veziris N. Bernard C. Guglielmetti L. Le Du D. Marigot-Outtandy D. Jaspard M. Caumes E. Lerat I. Rioux C. Yazdanpanah Y. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: Lessons to avoid repeating past errors Eur. Respir. J. 2017 49 3 10.1183/13993003.01719-2016 29. Somoskovi A. Bruderer V. Hömke R. Bloemberg G.V. Böttger E.C. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment Eur. Respir. J. 2015 45 554 557 10.1183/09031936.00142914 25359333 30. Tadolini M. Lingtsang R.D. Tiberi S. Enwerem M. D’Ambrosio L. Sadutshang T.D. Centis R. Migliori G.B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline Eur. Respir. J. 2016 48 935 938 10.1183/13993003.00637-2016 27288039 31. Harausz E.P. Chervenak K.A. Good C.E. Jacobs M.R. Wallis R.S. Sanchez-Felix M. Boom W.H. Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture Tuberculosis 2016 98 92 96 10.1016/j.tube.2016.03.002 27156623 32. Hancock R.E. Diamond G. The role of cationic antimicrobial peptides in innate host defences Trends Microbiol. 2000 8 402 410 10.1016/S0966-842X(00)01823-0 10989307 33. Ebenhan T. Gheysens O. Kruger H.G. Zeevaart J.R. Sathekge M.M. Antimicrobial peptides: Their role as infection-selective tracers for molecular imaging BioMed Res. Int. 2014 2014 867381 10.1155/2014/867381 25243191 34. Vilaplana C. Marzo E. Tapia G. Diaz J. Garcia V. Cardona P.-J. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis J. Infect. Dis. 2013 208 199 202 10.1093/infdis/jit152 23564636 35. Vilchèze C. Jacobs J. William R, The mechanism of isoniazid killing: Clarity through the scope of genetics Annu. Rev. Microbiol. 2007 61 35 50 10.1146/annurev.micro.61.111606.122346 18035606 36. Machado D. Perdigao J. Ramos J. Couto I. Portugal I. Ritter C. Boettger E.C. Viveiros M. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations J. Antimicrob. Chemother. 2013 68 1728 1732 10.1093/jac/dkt090 23539241 37. Petrini B. Hoffner S. Drug-resistant and multidrug-resistant tubercle bacilli Int. J. Antimicrob. Agents 1999 13 93 97 10.1016/S0924-8579(99)00111-9 10595567 38. Castelo-Branco F.S. de Lima E.C. de Oliveira Domingos J.L. Pinto A.C. Lourenço M.C.S. Gomes K.M. Costa-Lima M.M. Araujo-Lima C.F. Aiub C.A.F. Felzenszwalb I. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity Eur. J. Med. Chem. 2018 146 529 540 10.1016/j.ejmech.2018.01.071 29407978 39. Loots D.T. An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance Antimicrob. Agents Chemother. 2014 58 2144 2149 10.1128/AAC.02344-13 24468786 40. Rajkhowa S. C Deka R. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis Curr. Pharm. Des. 2014 20 4455 4473 10.2174/1381612819666131118165824 24245759 41. Reddy D.S. Kongot M. Netalkar S.P. Kurjogi M.M. Kumar R. Avecilla F. Kumar A. Synthesis and evaluation of novel coumarin-oxime ethers as potential anti-tubercular agents: Their DNA cleavage ability and BSA interaction study Eur. J. Med. Chem. 2018 150 864 875 10.1016/j.ejmech.2018.03.042 29597169 42. Mangasuli S.N. Hosamani K.M. Devarajegowda H.C. Kurjogi M.M. Joshi S.D. Synthesis of coumarin-theophylline hybrids as a new class of anti-tubercular and anti-microbial agents Eur. J. Med. Chem. 2018 146 747 756 10.1016/j.ejmech.2018.01.025 29407993 43. Adeniji A.A. Knoll K.E. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: A conspectus Appl. Microbiol. Biotechnol. 2020 104 5633 5662 10.1007/s00253-020-10606-y 32372202 44. Pires C.T. Scodro R.B. Cortez D.A. Brenzan M.A. Siqueira V.L. Caleffi-Ferracioli K.R. Vieira L.C. Monteiro J.L. Corrêa A.G. Cardoso R.F. Structure–activity relationship of natural and synthetic coumarin derivatives against Mycobacterium tuberculosis Future Med. Chem. 2020 12 1533 1546 10.4155/fmc-2018-0281 32820960 45. Kapp E. Visser H. Sampson S.L. Malan S.F. Streicher E.M. Foka G.B. Warner D.F. Omoruyi S.I. Enogieru A.B. Ekpo O.E. Versatility of 7-substituted coumarin molecules as antimycobacterial agents, neuronal enzyme inhibitors and neuroprotective agents Molecules 2017 22 1644 10.3390/molecules22101644 28973990 46. Dong M. Pfeiffer B. Altmann K.-H. Recent developments in natural product-based drug discovery for tuberculosis Drug Discov. Today 2017 22 585 591 10.1016/j.drudis.2016.11.015 27890820 47. Kling A. Lukat P. Almeida D.V. Bauer A. Fontaine E. Sordello S. Zaburannyi N. Herrmann J. Wenzel S.C. König C. Targeting DnaN for tuberculosis therapy using novel griselimycins Science 2015 348 1106 1112 10.1126/science.aaa4690 26045430 48. Holzgrabe U. New griselimycins for treatment of tuberculosis Chem. Biol. 2015 22 981 982 10.1016/j.chembiol.2015.08.002 26295835 49. Lukat P. Katsuyama Y. Wenzel S. Binz T. König C. Blankenfeldt W. Brönstrup M. Müller R. Biosynthesis of methyl-proline containing griselimycins, natural products with anti-tuberculosis activity Chem. Sci. 2017 8 7521 7527 10.1039/C7SC02622F 29163906 50. Arranz-Trullén J. Lu L. Pulido D. Bhakta S. Boix E. Host antimicrobial peptides: The promise of new treatment strategies against tuberculosis Front. Immunol. 2017 8 1499 10.3389/fimmu.2017.01499 29163551 51. Lee I.-G. Lee S.J. Chae S. Lee K.-Y. Kim J.-H. Lee B.-J. Structural and functional studies of the Mycobacterium tuberculosis VapBC30 toxin-antitoxin system: Implications for the design of novel antimicrobial peptides Nucl. Acids Res. 2015 43 7624 7637 10.1093/nar/gkv689 26150422 52. Gupta S. Winglee K. Gallo R. Bishai W.R. Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis J. Pathol. 2017 242 52 61 10.1002/path.4878 28097645 53. Rivas-Santiago B. Santiago C.E.R. Castañeda-Delgado J.E. León–Contreras J.C. Hancock R.E. Hernandez-Pando R. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 2013 41 143 148 10.1016/j.ijantimicag.2012.09.015 23141114 54. Jiang Z. P Higgins M. Whitehurst J. O Kisich K. I Voskuil M. S Hodges R. Anti-tuberculosis activity of α-helical antimicrobial peptides: De novo designed L-and D-enantiomers versus L-and D-LL37 Protein Pept. Lett. 2011 18 241 252 10.2174/092986611794578288 20858205 55. Sosunov V. Mischenko V. Eruslanov B. Svetoch E. Shakina Y. Stern N. Majorov K. Sorokoumova G. Selishcheva A. Apt A. Antimycobacterial activity of bacteriocins and their complexes with liposomes J. Antimicrob. Chemother. 2007 59 919 925 10.1093/jac/dkm053 17347179 56. Carroll J. Field D. O’Connor P.M. Cotter P.D. Coffey A. Hill C. O’Mahony J. The gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs Bioeng. Bugs 2010 1 408 412 10.4161/bbug.1.6.13642 21468208 57. Pereira T.M. Franco D.P. Vitorio F. Kummerle A.E. Coumarin compounds in medicinal chemistry: Some important examples from the last years Curr. Top. Med. Chem. 2018 18 124 148 10.2174/1568026618666180329115523 29595110 58. Neyts J. Clercq E.D. Singha R. Chang Y.H. Das A.R. Chakraborty S.K. Hong S.C. Tsay S.-C. Hsu M.-H. Hwu J.R. Structure−activity relationship of new anti-Hepatitis C virus agents: Heterobicycle−coumarin conjugates J. Med. Chem. 2009 52 1486 1490 10.1021/jm801240d 19193060 59. Tsay S.-C. Hwu J.R. Singha R. Huang W.-C. Chang Y.H. Hsu M.-H. Shieh F.-k. Lin C.-C. Hwang K.C. Horng J.-C. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus Eur. J. Med. Chem. 2013 63 290 298 10.1016/j.ejmech.2013.02.008 23501114 60. Manvar A. Bavishi A. Radadiya A. Patel J. Vora V. Dodia N. Rawal K. Shah A. Diversity oriented design of various hydrazides and their in vitro evaluation against Mycobacterium tuberculosis H37Rv strains Bioorganic Med. Chem. Lett. 2011 21 4728 4731 10.1016/j.bmcl.2011.06.074 61. Arshad A. Osman H. Bagley M.C. Lam C.K. Mohamad S. Zahariluddin A.S.M. Synthesis and antimicrobial properties of some new thiazolyl coumarin derivatives Eur. J. Med. Chem. 2011 46 3788 3794 10.1016/j.ejmech.2011.05.044 21712145 62. Farshori N.N. Banday M.R. Ahmad A. Khan A.U. Rauf A. 7-Hydroxy-coumarin derivatives: Synthesis, characterization and preliminary antimicrobial activities Med. Chem. Res. 2011 20 535 541 10.1007/s00044-010-9347-9 63. López-Rojas P. Janeczko M. Kubiński K. Amesty Á. Masłyk M. Estévez-Braun A. Synthesis and antimicrobial activity of 4-substituted 1, 2, 3-triazole-coumarin derivatives Molecules 2018 23 199 10.3390/molecules23010199 29346325 64. Kadhum A.A.H. Al-Amiery A.A. Musa A.Y. Mohamad A.B. The antioxidant activity of new coumarin derivatives Int. J. Mol. Sci. 2011 12 5747 5761 10.3390/ijms12095747 22016624 65. Witaicenis A. Seito L.N. da Silveira Chagas A. de Almeida Junior L.D. Luchini A.C. Rodrigues-Orsi P. Cestari S.H. Di Stasi L.C. Antioxidant and intestinal anti-inflammatory effects of plant-derived coumarin derivatives Phytomedicine 2014 21 240 246 10.1016/j.phymed.2013.09.001 24176844 66. Manojkumar P. Ravi T. Subbuchettiar G. Synthesis of coumarin heterocyclic derivatives with antioxidant activity and in vitro cytotoxic activity against tumour cells Acta Pharm. 2009 59 159 170 10.2478/v10007-009-0018-7 19564141 67. Sashidhara K.V. Kumar A. Chatterjee M. Rao K.B. Singh S. Verma A.K. Palit G. Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents Bioorganic Med. Chem. Lett. 2011 21 1937 1941 10.1016/j.bmcl.2011.02.040 68. Wang S.-B. Liu H. Li G.-Y. Li J. Li X.-J. Lei K. Wei L.-C. Quan Z.-S. Wang X.-K. Liu R.-M. Coumarin and 3, 4-dihydroquinolinone derivatives: Synthesis, antidepressant activity, and molecular docking studies Pharmacol. Rep. 2019 71 1244 1252 10.1016/j.pharep.2019.07.011 31670061 69. Sashidhara K.V. Rao K.B. Singh S. Modukuri R.K. Teja G.A. Chandasana H. Shukla S. Bhatta R.S. Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents Bioorganic Med. Chem. Lett. 2014 24 4876 4880 10.1016/j.bmcl.2014.08.037 70. Kontogiorgis C.A. Hadjipavlou-Litina D.J. Synthesis and antiinflammatory activity of coumarin derivatives J. Med. Chem. 2005 48 6400 6408 10.1021/jm0580149 16190766 71. Fylaktakidou K.C. Hadjipavlou-Litina D.J. Litinas K.E. Nicolaides D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities Curr. Pharm. Des. 2004 10 3813 3833 10.2174/1381612043382710 15579073 72. Bansal Y. Sethi P. Bansal G. Coumarin: A potential nucleus for anti-inflammatory molecules Med. Chem. Res. 2013 22 3049 3060 10.1007/s00044-012-0321-6 73. El-Haggar R. Al-Wabli R.I. Anti-inflammatory screening and molecular modeling of some novel coumarin derivatives Molecules 2015 20 5374 5391 10.3390/molecules20045374 25822078 74. Arora R.K. Kaur N. Bansal Y. Bansal G. Novel coumarin–benzimidazole derivatives as antioxidants and safer anti-inflammatory agents Acta Pharm. Sin. B 2014 4 368 375 10.1016/j.apsb.2014.07.001 26579406 75. Chen Z. Bi J. Su W. Synthesis and Antitumor Activity of Novel Coumarin Derivatives via a Three-component Reaction in Water Chin. J. Chem. 2013 31 507 514 10.1002/cjoc.201201130 76. Qin Q.-P. Wang Z.-F. Huang X.-L. Tan M.-X. Zou B.-Q. Liang H. Strong in vitro and vivo cytotoxicity of novel organoplatinum (II) complexes with quinoline-coumarin derivatives Eur. J. Med. Chem. 2019 184 111751 10.1016/j.ejmech.2019.111751 31593828 77. Musa M.A. Cooperwood J.S. Khan M.O.F. A review of coumarin derivatives in pharmacotherapy of breast cancer Curr. Med. Chem. 2008 15 2664 2679 10.2174/092986708786242877 18991629 78. Bisi A. Cappadone C. Rampa A. Farruggia G. Sargenti A. Belluti F. Di Martino R.M. Malucelli E. Meluzzi A. Iotti S. Coumarin derivatives as potential antitumor agents: Growth inhibition, apoptosis induction and multidrug resistance reverting activity Eur. J. Med. Chem. 2017 127 577 585 10.1016/j.ejmech.2017.01.020 28109950 79. Zhang W. Li Z. Zhou M. Wu F. Hou X. Luo H. Liu H. Han X. Yan G. Ding Z. Synthesis and biological evaluation of 4-(1, 2, 3-triazol-1-yl) coumarin derivatives as potential antitumor agents Bioorganic Med. Chem. Lett. 2014 24 799 807 10.1016/j.bmcl.2013.12.095 80. Alipour M. Khoobi M. Emami S. Fallah-Benakohal S. Ghasemi-Niri S.F. Abdollahi M. Foroumadi A. Shafiee A. Antinociceptive properties of new coumarin derivatives bearing substituted 3, 4-dihydro-2H-benzothiazines Daru J. Pharm. Sci. 2014 22 9 10.1186/2008-2231-22-9 81. Cheriyan B.V. Sr. Kadhirvelu P. Sr. Nadipelly J. Jr. Shanmugasundaram J. Sayeli V. Sr. Subramanian V. Sr. Anti-nociceptive effect of 7-methoxy coumarin from Eupatorium Triplinerve vahl (Asteraceae) Pharmacogn. Mag. 2017 13 81 28216887 82. Park S.-H. Sim Y.-B. Kang Y.-J. Kim S.-S. Kim C.-H. Kim S.-J. Lim S.-M. Suh H.-W. Antinociceptive profiles and mechanisms of orally administered coumarin in mice Biol. Pharm. Bull. 2013 36 925 930 10.1248/bpb.b12-00905 23727914 83. Sanchez-Recillas A. Navarrete-Vázquez G. Hidalgo-Figueroa S. Rios M.Y. Ibarra-Barajas M. Estrada-Soto S. Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs Eur. J. Med. Chem. 2014 77 400 408 10.1016/j.ejmech.2014.03.029 24681028 84. Leal L.K.A.M. Silva A.H. de Barros Viana G.S. Justicia pectoralis, a coumarin medicinal plant have potential for the development of antiasthmatic drugs? Rev. Bras. Farmacogn. 2017 27 794 802 10.1016/j.bjp.2017.09.005 85. Wang J. Fu Y. Wei Z. He X. Shi M. Kou J. Zhou E. Liu W. Yang Z. Guo C. Anti-asthmatic activity of osthole in an ovalbumin-induced asthma murine model Respir. Physiol. Neurobiol. 2017 239 64 69 10.1016/j.resp.2017.01.011 28143779 86. Piazzi L. Cavalli A. Colizzi F. Belluti F. Bartolini M. Mancini F. Recanatini M. Andrisano V. Rampa A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorganic Med. Chem. Lett. 2008 18 423 426 10.1016/j.bmcl.2007.09.100 17998161 87. Shaik J.B. Palaka B.K. Penumala M. Kotapati K.V. Devineni S.R. Eadlapalli S. Darla M.M. Ampasala D.R. Vadde R. Amooru G.D. Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents Eur. J. Med. Chem. 2016 107 219 232 10.1016/j.ejmech.2015.10.046 26588065 88. Patil P.O. Bari S.B. Firke S.D. Deshmukh P.K. Donda S.T. Patil D.A. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease Bioorganic Med. Chem. 2013 21 2434 2450 10.1016/j.bmc.2013.02.017 89. Ahmad R. Asad M. Siddiqui Z.N. Evaluation of antipyretic and antinociceptive potential of new heterocyclic derivatives of 3-formyl-4-hydroxycoumarin in rats Int. Res. J. Pharm. Appl. Sci. 2013 3 253 259 90. El-Sharkawy K.A. AlBratty M.M. Alhazmi H.A. Synthesis of some novel pyrimidine, thiophene, coumarin, pyridine and pyrrole derivatives and their biological evaluation as analgesic, antipyretic and anti-inflammatory agents Braz. J. Pharm. Sci. 2018 54 10.1590/s2175-97902018000400153 91. Sashidhara K.V. Kumar A. Kumar M. Sonkar R. Bhatia G. Khanna A. Novel coumarin derivatives as potential antidyslipidemic agents Bioorganic Med. Chem. Lett. 2010 20 4248 4251 10.1016/j.bmcl.2010.05.023 92. Sashidhara K.V. Kumar A. Kumar M. Srivastava A. Puri A. Synthesis and antihyperlipidemic activity of novel coumarin bisindole derivatives Bioorganic Med. Chem. Lett. 2010 20 6504 6507 10.1016/j.bmcl.2010.09.055 93. Asif M. Pharmacologically potentials of different substituted coumarin derivatives Chem. Int. 2015 1 1 11 94. Pari L. Rajarajeswari N. Saravanan S. Rathinam A. Antihyperlipidemic effect of coumarin in experimental type 2 diabetic rats Biomed. Prev. Nutr. 2014 4 171 176 10.1016/j.bionut.2014.02.003 95. Keri R.S. Sasidhar B. Nagaraja B.M. Santos M.A. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents Eur. J. Med. Chem. 2015 100 257 269 10.1016/j.ejmech.2015.06.017 26112067 96. Yang F. Zhao N. Song J. Zhu K. Jiang C.-s. Shan P. Zhang H. Design, synthesis and biological evaluation of novel coumarin-based hydroxamate derivatives as histone deacetylase (hdac) inhibitors with antitumor activities Molecules 2019 24 2569 10.3390/molecules24142569 97. Abdizadeh T. Kalani M.R. Abnous K. Tayarani-Najaran Z. Khashyarmanesh B.Z. Abdizadeh R. Ghodsi R. Hadizadeh F. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents Eur. J. Med. Chem. 2017 132 42 62 10.1016/j.ejmech.2017.03.024 28340413 98. Niu H. Wang W. Li J. Lei Y. Zhao Y. Yang W. Zhao C. Lin B. Song S. Wang S. A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies Eur. J. Med. Chem. 2017 138 212 220 10.1016/j.ejmech.2017.06.033 28667876 99. Terlain B. Thomas J. Structure of griselimycin, polypeptide antibiotic extracted from streptomyces cultures. II. Structure of griselimycin Bull. Soc. Chim. Fr. 1971 6 2357 5568643 100. Herrmann J. Rybniker J. Müller R. Novel and revisited approaches in antituberculosis drug discovery Curr. Opin. Biotechnol. 2017 48 94 101 10.1016/j.copbio.2017.03.023 28427007 101. Brogden K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005 3 238 250 10.1038/nrmicro1098 15703760 102. Nguyen L.T. Haney E.F. Vogel H.J. The expanding scope of antimicrobial peptide structures and their modes of action Trends Biotechnol. 2011 29 464 472 10.1016/j.tibtech.2011.05.001 21680034 103. Fjell C.D. Hiss J.A. Hancock R.E. Schneider G. Designing antimicrobial peptides: Form follows function Nat. Rev. Drug Discov. 2012 11 37 51 10.1038/nrd3591 22173434 104. Giuliani A. Pirri G. Nicoletto S. Antimicrobial peptides: An overview of a promising class of therapeutics Open Life Sci. 2007 2 1 33 10.2478/s11535-007-0010-5 105. Bahar A.A. Ren D. Antimicrobial peptides Pharmaceuticals 2013 6 1543 1575 10.3390/ph6121543 24287494 106. Pushpanathan M. Gunasekaran P. Rajendhran J. Antimicrobial peptides: Versatile biological properties Int. J. Pept. 2013 2013 675391 10.1155/2013/675391 23935642 107. Jindal M. Le C. Mohd Yusof M. Sekaran S. Net charge, hydrophobicity and specific amino acids contribute to the activity of antimicrobial peptides J. Health Transl. Med. 2014 17 1 7 108. Abedinzadeh M. Gaeini M. Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis J. Antimicrob. Chemother. 2015 70 1285 1289 10.1093/jac/dku570 25681127 109. Kang S.-J. Kim D.-H. Mishig-Ochir T. Lee B.-J. Antimicrobial peptides: Their physicochemical properties and therapeutic application Arch. Pharmacal Res. 2012 35 409 413 10.1007/s12272-012-0302-9 110. Linde C.M. Hoffner S.E. Refai E. Andersson M. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis J. Antimicrob. Chemother. 2001 47 575 580 10.1093/jac/47.5.575 11328767 111. Hao G. Shi Y.-H. Tang Y.-L. Le G.-W. The intracellular mechanism of action on Escherichia coli of BF2-A/C, two analogues of the antimicrobial peptide Buforin 2 J. Microbiol. 2013 51 200 206 10.1007/s12275-013-2441-1 23625221 112. Fattorini L. Gennaro R. Zanetti M. Tan D. Brunori L. Giannoni F. Pardini M. Orefici G. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis Peptides 2004 25 1075 1077 10.1016/j.peptides.2004.04.003 15245864 113. Lan Y. Lam J.T. Siu G.K. Yam W.C. Mason A.J. Lam J.K. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis Tuberculosis 2014 94 678 689 10.1016/j.tube.2014.08.001 25154927 114. Rivas-Santiago B. Hernandez-Pando R. Carranza C. Juarez E. Contreras J.L. Aguilar-Leon D. Torres M. Sada E. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells Infect. Immun. 2008 76 935 941 10.1128/IAI.01218-07 18160480 115. Santos J.C. Silva-Gomes S. Silva J.P. Gama M. Rosa G. Gallo R.L. Appelberg R. Endogenous cathelicidin production limits inflammation and protective immunity to Mycobacterium avium in mice Immun. Inflamm. Dis. 2014 2 1 12 10.1002/iid3.7 25400920 116. Chatterjee C. Paul M. Xie L. Van Der Donk W.A. Biosynthesis and mode of action of lantibiotics Chem. Rev. 2005 105 633 684 10.1021/cr030105v 15700960 117. Guinane C. Cotter P. Hill C. Ross R. Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food J. Appl. Microbiol. 2005 98 1316 1325 10.1111/j.1365-2672.2005.02552.x 15916645 118. Carroll J. Draper L.A. O’Connor P.M. Coffey A. Hill C. Ross R.P. Cotter P.D. O’Mahony J. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria Int. J. Antimicrob. Agents 2010 36 132 136 10.1016/j.ijantimicag.2010.03.029 20547041 119. Yuk J.-M. Shin D.-M. Lee H.-M. Yang C.-S. Jin H.S. Kim K.-K. Lee Z.-W. Lee S.-H. Kim J.-M. Jo E.-K. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin Cell Host Microbe 2009 6 231 243 10.1016/j.chom.2009.08.004 19748465